Golden moment for Aurinia stock after rapid resolution of patent dispute

4 January 2023

Canadian firm Aurinia Pharmaceuticals (Nasdaq: AUPH) and India’s Sun Pharmaceutical (BSE: 524715) have moved quickly to settle a patent dispute in the US market.

The firms have filed a joint motion to terminate an inter partes review which was initiated by the US Patent Trial and Appeal Board (PTAB) after a petition was filed by Sun Pharma in the summer of 2022.

The dispute relates to a US patent held by Aurinia for Lupkynis (voclosporin), which would extend the product’s exclusivity in the USA to 2037.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK